CASE STUDY : BRISTOL-MEYERS SQUIBB 2011
< FACULTY >
< SEMESTER / YEAR>
< COURSE CODE>
< COURSE TITLE>
MATRICULATION NO :
IDENTITY CARD NO. :
TELEPHONE NO. :
E-MAIL :
LEARNING CENTRE :
TABLE OF CONTENT
CASE STUDY : BRISTOL-MEYERS SQUIBB 2011
1. Case Abstract
Bristol Meyers Squibb (BMY) is a comprehensive strategic management case that includes the company’s year-end 2010 financial statements, organizational chart, competitor information and more. The case time setting is the year 2011. Sufficient internal and external data are provided to enable evaluation of current strategies and to recommend a strategic plan for the company.
BMY’s second quarter 2011 financial result revealed a sale increase of 14 percent to $5.4 billion, exceeding analysts’ expectations. BMY’s earnings in the quarter decreased 2 percent to $0.52 per share. The excellent results were driven by an impressive showing of BMY’s leading drugs including blood thinner Plavix which the company co-developed with Sanofi-Aventis.
Headquartered in New York City, Bristol-Myers Squibb is a huge pharmaceutical firm with such blockbuster cardiovascular drugs as Plavix and Avapro for hypertension. BMY also produces antipsychotic medication Abilify and HIV treatments Reyataz and Sustiva. BMY also has excellent products in immunoscience, metabolics, neuroscience, oncology, and virology. BMY has 12 manufacturing plants worldwide and conducts research and development in four countries, sells its products globally; the US accounts for two thirds of BMY’s sales. The year 2011 has been fruitful for Bristol-Myers with many key drugs getting approved as the company aims to combat the pendeng genericization of some of its key drugs including the blockbuster blood-thinner Plavix. BMY has an excellent pipeline of drugs that should get approved in the next twelve months.
2. Vision Statement
Proposed vision statement for BMY is as below:
“To embody global
< SEMESTER / YEAR>
< COURSE CODE>
< COURSE TITLE>
MATRICULATION NO :
IDENTITY CARD NO. :
TELEPHONE NO. :
E-MAIL :
LEARNING CENTRE :
TABLE OF CONTENT
CASE STUDY : BRISTOL-MEYERS SQUIBB 2011
1. Case Abstract
Bristol Meyers Squibb (BMY) is a comprehensive strategic management case that includes the company’s year-end 2010 financial statements, organizational chart, competitor information and more. The case time setting is the year 2011. Sufficient internal and external data are provided to enable evaluation of current strategies and to recommend a strategic plan for the company.
BMY’s second quarter 2011 financial result revealed a sale increase of 14 percent to $5.4 billion, exceeding analysts’ expectations. BMY’s earnings in the quarter decreased 2 percent to $0.52 per share. The excellent results were driven by an impressive showing of BMY’s leading drugs including blood thinner Plavix which the company co-developed with Sanofi-Aventis.
Headquartered in New York City, Bristol-Myers Squibb is a huge pharmaceutical firm with such blockbuster cardiovascular drugs as Plavix and Avapro for hypertension. BMY also produces antipsychotic medication Abilify and HIV treatments Reyataz and Sustiva. BMY also has excellent products in immunoscience, metabolics, neuroscience, oncology, and virology. BMY has 12 manufacturing plants worldwide and conducts research and development in four countries, sells its products globally; the US accounts for two thirds of BMY’s sales. The year 2011 has been fruitful for Bristol-Myers with many key drugs getting approved as the company aims to combat the pendeng genericization of some of its key drugs including the blockbuster blood-thinner Plavix. BMY has an excellent pipeline of drugs that should get approved in the next twelve months.
2. Vision Statement
Proposed vision statement for BMY is as below:
“To embody global